Company intelligence / Profile preview
CytoMed Therapeutics China
Singapore, Singapore
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
CytoMed Therapeutics is a Singapore-based clinical-stage biopharmaceutical company developing donor-derived allogeneic cell therapies. Its lead CAR-γδ T cell product CTM-N2D is in a first-in-human Phase I trial in Singapore for advanced solid and blood cancers, with a Phase II investigator-initiated trial planned in India. Early dosing in the ANGELICA trial has been completed, with initial safety readout expected around end-2025.[1][3][4][6]
- Therapeutic areas
- HematologyImmunologyNeurologyRheumatologyOncology
- Modalities
- Cell therapyCAR-T cell therapyNK cell therapyStem cell therapyInduced pluripotent stem cell derived therapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
SunAct Cancer Institute Private Limited (India) – Phase II IIT using CytoMed-manufactured gamma delta T cells for various cancers[1][6]Hangzhou CNK Therapeutics Co., Ltd (China) – MOU to use PiggyBac non-viral gene editing for CAR integration and potential China JV for clinical trials[5]Sengkang General Hospital (Singapore) – research collaboration on injectable umbilical cord-derived mesenchymal stem cells for cartilage diseases and osteoarthritis[4][6]
Beyond the preview
Go deeper on CytoMed Therapeutics China.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CytoMed Therapeutics China.